Omics Technology facility

核心技术开发一直是本财年的重点。我们正在建立基于NGS的技术，以发现癌症驱动因素，并了解生物机制。具体而言，以下技术已经建立或接近建立。1.用于癌症突变检测的NGS。我们采用了DNA和RNA外显子组测序的方法，旨在检测SNV，缺失，插入。2.用于表达和融合检测的NGS。实验室的工作人员接受了RNA外显子组测序的培训，以检测融合和表达分析。3.表观遗传调节。我们采用了两种不同的芯片测序方法，包括抗体介导的微球菌核酸酶和转座DNA切割。4.癌症基因组的靶向测序5.定制的检测开发和参与T细胞介导的抗肿瘤抗原应答的基因测序6.分别验证NGS方法用于其预期研究或临床用途7。完善NGS数据分析的分析管道。8.使用FISH、RNAScope和其他基于荧光的方法研究肿瘤异质性。

Core technology development has been the main focus during this fiscal year. We are in the process of establishing NGS-based technologies for the discovery of cancer drivers, and for understanding biological mechanisms. Specifically, the following technologies are established or near establishment. 1. NGS for cancer mutation detection. We adapted methods for both DNA and RNA Exome sequencing aimed for detection SNV, deletion, an insertion. 2. NGS for expression and fusion detection. The staff in the lab were trained for RNA Exome seq for the detection of fusions, and for expression analysis. 3. Epigenetic regulation. We adapted two different methods for chip-seq, including antibody-mediated DNA cutting by micrococcal nucleases and transposes. 4. Targeted sequencing of cancer gene panels 5. Customized assay development and sequencing of genes involved in T-cell mediated responses against tumor antigens 6. Validation of the NGS methods for their intended research or clinical use, respectively 7. Refining the analytical pipelines for NGS data analysis. 8. Investigating tumor heterogeneity using FISH, RNAScope, and other fluorescent based methods.